Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CNTX logo CNTX
Upturn stock ratingUpturn stock rating
CNTX logo

Context Therapeutics Inc (CNTX)

Upturn stock ratingUpturn stock rating
$0.74
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

03/27/2025: CNTX (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type Stock
Historic Profit -51.55%
Avg. Invested days 35
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 03/27/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 58.77M USD
Price to earnings Ratio -
1Y Target Price 6.25
Price to earnings Ratio -
1Y Target Price 6.25
Volume (30-day avg) 93561
Beta 2.06
52 Weeks Range 0.64 - 2.75
Updated Date 03/30/2025
52 Weeks Range 0.64 - 2.75
Updated Date 03/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.46

Earnings Date

Report Date 2025-03-21
When -
Estimate -0.092
Actual -0.0373

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -32.76%
Return on Equity (TTM) -49.89%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -35445227
Price to Sales(TTM) -
Enterprise Value -35445227
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA 1.6
Shares Outstanding 89704200
Shares Floating 40555266
Shares Outstanding 89704200
Shares Floating 40555266
Percent Insiders 2.33
Percent Institutions 81.43

Analyst Ratings

Rating 4.4
Target Price 7.7
Buy 3
Strong Buy 2
Buy 3
Strong Buy 2
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Context Therapeutics Inc

stock logo

Company Overview

History and Background

Context Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing therapies for hormone-driven cancers. Founded to address unmet needs in women's oncology, the company has evolved through preclinical and clinical development stages. Specific founding year and earlier detailed milestones require accessing proprietary information.

Core Business Areas

  • Apremilast Development: Development of onapristone extended release (ONA-XR), an oral progesterone receptor (PR) antagonist, for the treatment of PR+ cancers. Focus is on clinical trials for various cancer types.

Leadership and Structure

Details on leadership and specific structure would require access to non-public organizational charts. The company is led by its CEO and has a management team overseeing clinical development, research, and business operations.

Top Products and Market Share

Key Offerings

  • Onapristone Extended Release (ONA-XR): ONA-XR is the lead product candidate, an oral progesterone receptor (PR) antagonist in Phase 2 clinical trials. Market share is currently 0, as it is still in development. Potential competitors include existing hormonal therapies and emerging PR antagonists.

Market Dynamics

Industry Overview

The pharmaceutical industry, specifically in oncology, is characterized by high research and development costs, stringent regulatory requirements, and intense competition. The market is driven by unmet medical needs and advancements in targeted therapies.

Positioning

Context Therapeutics is positioned as a company focused on hormone-driven cancers, particularly through its progesterone receptor antagonist ONA-XR. Its competitive advantage lies in its novel approach targeting PR+ cancers.

Total Addressable Market (TAM)

The TAM for hormone-driven cancers is significant, estimated in the billions of dollars annually. Context Therapeutics' positioning within this TAM is targeted towards specific PR+ cancer subtypes with unmet needs, representing a subset of the overall market.

Upturn SWOT Analysis

Strengths

  • Novel therapeutic approach targeting progesterone receptor
  • Lead product candidate in clinical trials
  • Experienced management team

Weaknesses

  • Limited financial resources compared to larger pharmaceutical companies
  • Dependence on successful clinical trial outcomes
  • Single lead product candidate creates concentration risk

Opportunities

  • Positive clinical trial results leading to regulatory approval
  • Partnerships with larger pharmaceutical companies
  • Expansion of pipeline through additional indications or therapeutic candidates

Threats

  • Clinical trial failures
  • Competition from established therapies and emerging competitors
  • Regulatory hurdles and delays
  • Changes in the healthcare landscape and reimbursement policies

Competitors and Market Share

Key Competitors

  • ARRY
  • PFE
  • AZN

Competitive Landscape

Context Therapeutics faces competition from established pharmaceutical companies and other biotechnology firms developing therapies for hormone-driven cancers. Its competitive advantage lies in its targeted approach to progesterone receptor antagonism.

Major Acquisitions

Growth Trajectory and Initiatives

Historical Growth: Historical growth is primarily measured by progress in clinical development rather than revenue generation.

Future Projections: Future growth is dependent on successful clinical trials and potential regulatory approvals. Analyst estimates would be needed for specific projections.

Recent Initiatives: Recent initiatives include advancing clinical trials for ONA-XR and exploring potential partnerships.

Summary

Context Therapeutics is a development-stage company focused on hormone-driven cancers, particularly through its lead candidate ONA-XR. Its success hinges on positive clinical trial outcomes. The company's limited financial resources and dependence on a single product candidate pose significant risks, but successful development could lead to substantial market opportunities. Close monitoring of trial results and strategic partnerships are crucial for its future growth.

Similar Companies

  • ARRY
  • PFE
  • AZN

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • ClinicalTrials.gov

Disclaimers:

The information provided is for informational purposes only and should not be considered financial advice. The analysis is based on publicly available information and may not be exhaustive.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Context Therapeutics Inc

Exchange NASDAQ
Headquaters Philadelphia, PA, United States
IPO Launch date 2021-10-20
Co-Founder, President, CEO & Director Mr. Martin A. Lehr
Sector Healthcare
Industry Biotechnology
Full time employees 12
Full time employees 12

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​